Myeloma Center

Bibliography

Found 47 results
Author Title Type [ Year(Asc)]
Filters: Author is Niesvizky, Ruben  [Clear All Filters]
2018
Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng W-J, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S et al..  2018.  Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.. Leuk Lymphoma. 59(6):1364-1374.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma.. Cancer Res. 78(10):2747-2759.
Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu J-M, Niesvizky R et al..  2018.  Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices.. Biol Blood Marrow Transplant. 24(2):288-293.
2017
Boussi L, Niesvizky R.  2017.  Advances in immunotherapy in multiple myeloma.. Curr Opin Oncol. 29(6):460-466.
Ludwig H, Dimopoulos MA, Moreau P, Chng W-J, Goldschmidt H, Hajek R, Facon T, Pour L, Niesvizky R, Oriol A et al..  2017.  Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.. Leuk Lymphoma. 58(10):2501-2504.
Dimopoulos MA, A Stewart K, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V et al..  2017.  Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.. Br J Haematol. 177(3):404-413.
Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R et al..  2017.  Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.. Lancet Oncol. 18(10):1327-1337.
Ely S, Forsberg P, Ouansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D et al..  2017.  Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.. Clin Lymphoma Myeloma Leuk. 17(12):825-833.
Jhaveri KD, Niesvizky R.  2017.  High-Cutoff Hemodialysis in Myeloma Cast Nephropathy.. JAMA. 318(21):2085-2086.
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D et al..  2017.  Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies.. J Clin Invest. 127(6):2066-2080.
Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM et al..  2017.  IgM myeloma: A multicenter retrospective study of 134 patients.. Am J Hematol. 92(8):746-751.
Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T et al..  2017.  A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.. Biol Blood Marrow Transplant. 23(6):930-937.
Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, Dimopoulos MA, A Stewart K, Badros A, Papadopoulos KP et al..  2017.  Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma.. J Clin Pharmacol. 57(5):663-677.
2016
Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Spicka I, Masszi T, Hajek R, Rosiñol L, Goranova-Marinova V, Mihaylov G et al..  2016.  Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.. Blood. 128(9):1174-80.
Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT et al..  2016.  Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.. Br J Haematol. 175(5):884-891.
Braunstein M, Niesvizky R.  2016.  Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma.. Semin Oncol. 43(6):709-711.
A Stewart K, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ et al..  2016.  Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.. J Clin Oncol. 34(32):3921-3930.
2015
A Stewart K, S Rajkumar V, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosiñol L, Siegel DS, Mihaylov GG et al..  2015.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.. N Engl J Med. 372(2):142-52.
Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A.  2015.  Clinical characteristics of patients with relapsed multiple myeloma.. Cancer Treat Rev. 41(10):827-35.
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R et al..  2015.  Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.. J Clin Oncol. 33(33):3921-9.
Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S et al..  2015.  Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. Leuk Lymphoma. 56(12):3320-8.
Krishnan U, Mark TM, Niesvizky R, Sobol I.  2015.  Pulmonary hypertension complicating multiple myeloma.. Pulm Circ. 5(3):590-7.
Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS.  2015.  Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.. Leuk Lymphoma. 56(10):2959-61.
2014
Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA.  2014.  IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.. Mod Pathol. 27(3):375-81.
Palumbo A, S Rajkumar V, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC et al..  2014.  International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.. J Clin Oncol. 32(6):587-600.